Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cosmic: setrusumab versus bisphosphonates in young children with osteogenesis imperfecta
2023-504196-24-00Phase 3Authorised
- Sponsor
- Ultragenyx Pharmaceutical Inc.
- Start
- Oct 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 8
01
Overview
Phase 3, randomised, open-label trial of setrusumab in osteogenesis imperfecta (OI) (2 arms), sponsored by Ultragenyx Pharmaceutical Inc. Primary endpoint: Annualized rate of all radiographically confirmed fractures including morphometric vertebral fractures. Planned start Oct 2023; status: authorised.
02
Drugs
setrusumab
03
Conditions
osteogenesis imperfecta (OI)
Beyond the preview
Go deeper on 2023-504196-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504196-24-00.